Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.59 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319049 | 0.89 | CHRM1 (0.70) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL3142425 | 0.85 | CHRM1 (0.81) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL4084782 | 0.85 | CHRM1 (0.76) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL3146496 | 0.84 | CHRM2 (0.83) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL29467164 | 0.83 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL44492 | 0.83 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL8863641 | 0.83 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL7008960 | 0.82 | ALDH1A1 (0.52) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL2255984 | 0.81 | CHRM1 (0.62) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL342295 | 0.81 | CHRM1 (0.62) | CHRM1CHRM2CHRM4CHRM3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | WYETH (US) | 2007-12-27 | — | — | US | claimed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| EP-0739891-B1 | Substituted heterocycles | ASTRAZENECA AB (SE) | 2005-01-19 | — | — | EP | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| US-6653295-B2 | Protease inhibitor; viricide | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-25 | — | — | US | claimed |
| EP-0680962-B1 | Heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-08-20 | — | — | EP | claimed |
| US-20030064962-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-04-03 | — | — | US | claimed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| EP-0734383-B1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | claimed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | claimed |
| EP-0739891-A2 | Substituted heterocycles | ZENECA LIMITED (GB) | 1996-10-30 | — | — | EP | claimed |
| WO-1995016682-A1 | CYCLIC AMIDE DERIVATIVES AS NEUROKININ A ANTAGONISTS | ZENECA LIMITED (GB) | 1995-06-22 | — | — | WO | claimed |
| US-4487774-A | Isochromans | THE UPJOHN COMPANY (US) | 1984-12-11 | — | — | US | claimed |
| EP-1926721-B1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | MSD ITALIA SRL (IT) | 2016-05-04 | — | — | EP | disclosed |
| US-8435973-B2 | 17-beta HSD1 and STS inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| EP-1888615-B1 | 17 -HSD1 AND STS INHIBITORS | ABBOTT PRODUCTS GMBH (DE) | 2012-05-16 | — | — | EP | disclosed |
| US-4148796-A | γ-Piperidinobutyrophenones | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1979-04-10 | — | — | US | disclosed |
| US-3996362-A | ANTIDEPRESSANTS, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3951978-A | ANALGESIC, ANTIARRHYTHMIC, CENTRAL NERVOUS DEPRESSANT | ISTITUTO LUSO FARMACO D'ITALIA S.R.L. (IT) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | HCAR2, PCCA, MCCC2 | CHRM1 2120/4885CHRM2 613/4885CHRM4 2401/4885 |
| US-20030064962-A1 | Inhibitors of hepatitis C virus NS3 protease | PRSS1, SERPINB1, SPINT2 | CHRM1 4863/4885CHRM2 4881/4885CHRM4 4879/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | CHRM1 905/4885CHRM2 1185/4885CHRM4 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.